BioSpace News Archive

Biotheryx, Inc. today announced the appointment of Jeff Caravella as Chief Financial Officer.

Silence Therapeutics plc today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (“Hansoh”) following the achievement of an undisclosed preclinical milestone.

NeoGenomics, Inc. announced today that they are partnering with Eli Lilly and Company on a sponsored testing program for eligible patients with metastatic non-small cell lung cancer (NSCLC) at no cost.

Starton Therapeutics Inc. announced that it has dosed the first subjects in a first-in-human Phase 1 STAR-LLD clinical trial of its investigational continuous delivery lenalidomide, in healthy subjects.

Ocugen, Inc. announced today that the independent Data and Safety Monitoring Board (DSMB) for its Phase 1/2 clinical trial of OCU400 reviewed safety data based on dosing to date and recommended that the study proceed with enrolling additional subjects.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has formed a joint venture, Visirna Therapeutics, with Vivo Capital to expand the reach of innovative medicines in Greater China.

Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced publication of a preclinical report on petosemtamab (Peto, MCLA-158: LGR5 x EGFR Biclonics®) in the journal Nature Cancer.

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release first quarter 2022 financial results before the market opens on Wednesday, April 27, 2022.

Cognition Therapeutics, Inc. announced that members of its management team will participate in a virtual fireside chat at the B. Riley Securities’ Neuro & Ophthalmology Conference taking place from April 27-28, 2022.

Astellas Pharma US, Inc. announced that it is accepting applications for the sixth annual Astellas Oncology C3 Prize, a global challenge that funds and advances the best non-treatment ideas to improve cancer care for patients, caregivers and the broader oncology community.